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Abstract
Background:  Parkinson's disease (PD) is a neurological disorder characterized by the degeneration of nigrostriatal
dopaminergic systems. Free radicals induced by oxidative stress are involved in the mechanisms of cell death in PD. This study
clarifies the neuroprotective effects of edaravone (MCI-186, 3-methyl-1-phenyl-2-pyrazolin-5-one), which has already been used
for the treatment of cerebral ischemia in Japan, on TH-positive dopaminergic neurons using PD model both in vitro and in vivo.
6-hydroxydopamine (6-OHDA), a neurotoxin for dopaminergic neurons, was added to cultured dopaminergic neurons derived
from murine embryonal ventral mesencephalon with subsequet administration of edaravone or saline. The number of surviving
TH-positive neurons and the degree of cell damage induced by free radicals were analyzed. In parallel, edaravone or saline was
intravenously administered for PD model of rats receiving intrastriatal 6-OHDA lesion with subsequent behavioral and
histological analyses.
Results: In vitro study showed that edaravone significantly ameliorated the survival of TH-positive neurons in a dose-responsive
manner. The number of apoptotic cells and HEt-positive cells significantly decreased, thus indicating that the neuroprotective
effects of edaravone might be mediated by anti-apoptotic effects through the suppression of free radicals by edaravone. In vivo
study demonstrated that edaravone-administration at 30 minutes after 6-OHDA lesion reduced the number of amphetamine-
induced rotations significantly than edaravone-administration at 24 hours. Tyrosine hydroxylase (TH) staining of the striatum
and substantia nigra pars compacta revealed that edaravone might exert neuroprotective effects on nigrostriatal dopaminergic
systems. The neuroprotective effects were prominent when edaravone was administered early and in high concentration.
TUNEL, HEt and Iba-1 staining in vivo might demonstrate the involvement of anti-apoptotic, anti-oxidative and anti-inflammatory
effects of edaravone-administration.
Conclusion: Edaravone exerts neuroprotective effects on PD model both in vitro and in vivo. The underlying mechanisms might
be involved in the anti-apoptotic effects, anti-oxidative effects, and/or anti-inflammatory effects of edaravone. Edaravone might
be a hopeful therapeutic option for PD, although the high therapeutic dosage remains to be solved for the clinical application.
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Background
Parkinson's disease (PD) is a neurodegenerative disorder
characterized by slowly progressive degeneration of DA
neurons in the substantia nigra pars compacta, with sub-
sequent damage of nerve terminals accompanied by
dopamine (DA) depletion in the striatum [1]. Although
the neuropathological hallmarks of PD are well described,
the etiology remains still undefined. However, accumula-
tive evidences revealed many biochemical processes and
molecular mechanisms as mediators of neuronal cell
death in PD. Notably oxidative stress and mitochondrial
dysfunction might be an important pillar of pathogenesis
of PD [2].
6-hydroxydopamine (6-OHDA) is widely used for experi-
mental models of PD [3]. It damages cells with dopamin-
ergic neuronal attribute, including human neuroblastoma
SH-SY5Y [4], PC12 cells derived from rat pheochromocy-
toma [5] and rat ventral mesencephalic neurons [6]. Fur-
thermore, it is also a specific neurotoxin for DA neurons
in vivo [2,7]. Intracellular lipids, proteins or DNA are dam-
aged with consequent impairment of cell function
induced by 6-OHDA. Mitochondrial oxidative phosphor-
ylation with subsequent energy deprivation and excre-
ment of 6-OHDA-auto-oxidation, including quinones
and hydrogen peroxide (H2O2) are deeply involved in the
cytotoxic processes [8]. As above described, mitochon-
drial dysfunction and oxidative stress might play impor-
tant roles in the pathogenesis of PD [2], thus indicating
that the experimental model using 6-OHDA might have
essential mechanisms in common with PD. Furthermore,
anti-oxidant agents, such as catalase, vitamin E, N-acetyl
cysteine, ascorbic acid and pyruvate might exert neuropro-
tection for 6-OHDA-treated DA neurons [9].
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a
potent scavenger of hydroxyl radicals, and is useful for
patients suffering from ischemic stroke [10,11], with the
involvement of peroxidation leading to neuronal cell
death [12]. Neuroprotective effects of edaravone are
explored using head trauma [13] and spinal cord ischemia
[14]. Recent study demonstrated that edaravone suppress
the production of nitric oxide and reactive oxygen species
by activated microglia [15]. In both cerebral ischemia and
PD, free radicals might be one of the critical pathogenesis
which accelerates progression of disease. These results
suggest that edaravone might have neuroprotective effects
on 6-OHDA-treated DA neurons and might on slowly
degenerated DA neurons in PD patients through anti-oxi-
dative mechanisms.
In this study, first we explored the neuroprotective effects
of edaravone on 6-OHDA-induced toxicity against
murine ventral mesencephalic (VM) cell cultures and the
underlying mechanisms. After confirming the effects in
vitro, edaravone was intravenously administered to 6-
OHDA-lesioned PD model of rats and evaluated behavio-
rally and immunohistochemically.
Methods
In vitro model of Parkinson's disease
Cell preparation
Murine DA neurons were cultured as described previously
with minor modifications [16]. Tissue blocks of the ven-
tral mesencephalon containing DA neurons were dis-
sected from murine embryo (C57/B6) on day 14 of
gestation after cervical dislocation with consequent tritu-
ration into single cell suspension. Cells were plated in
mixed hormone MEM (MHM) supplemented with 1%
fetal bovine serum at a density of 1 × 105 cells/well on
poly-D-ornithine and fibronectin-coated glass slides in
24-well plates (Nunc, Frankfurt, FRG). Cultures were
maintained at 37 degrees C in an atmosphere of 5% CO2
plus 95% air and with 100% relative humidity. Forty-
eight hours after initial plating, the medium was
exchanged and the cells were used for the further experi-
ments. The average number of mesencephalic neurons
was 0.42 ± 0.07 × 105 cells/well at the beginning of the
experiment with TH-immunoreactivity in 37 ± 12% of
total cells.
Administration of 6-OHDA and edaravone
Edaravone (MCI-186, 3-methyl-1-phenyl-2-pyrazolin-5-
one) was kindly provided from Mitsubishi Pharma
(Japan). It was dissolved in 0.5 ml of 1 N NaOH and 8 ml
of distilled water, and adjusted to pH 7 by addition of 1 N
HCl. At 48 hours after the initial plating, the cultured cells
were exposed to 40 μM 6-OHDA (Sigma) or PBS for 30
minutes, and then added 10-6, 10-5, 10-4 or 10-3 M edar-
avone, or saline as a control at 37 degrees C. The cells were
incubated for 18 hours and developed to immunocyto-
chemical investigations.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde (PFA) for 30
minutes and then washed three times for 5 minutes in
PBS. They were incubated overnight at 4 degrees C with an
antibody directed against tyrosine hydroxylase (TH, rab-
bit polyclonal IgG, 1: 500, Chemicon) with 10% normal
goat serum (Vector). After several rinses in PBS, cells were
incubated at room temperature for 30 minutes in sheep
anti-rabbit IgG FITC conjugate (1: 500, Sigma) and 4',6-
diamidino-2-phenylindole, dilactate (DAPI, 1: 500,
Molecular Probes). The cells were then washed three times
in PBS and mounted on albumin-coated slides and
embedded with cover glass. After photographically cap-
tured, immunoreactive neurons were counted per high
power field view selected at random (n = 3 in each well,
10,000 μm2). Six wells were assigned to each group for
statistical analyses. Control studies involved exclusion ofBMC Neuroscience 2008, 9:75 http://www.biomedcentral.com/1471-2202/9/75
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primary antibody substituted with 10% normal goat
serum in PBS. No immunoreactivity was observed in these
controls.
TUNEL staining and HEt staining
In order to explore the involvement of apoptosis in this
study, a modified method for terminal deoxynucleotidyl
transferase-mediated biotinylated UTP nick end labeling
(TUNEL, Roche) and DAPI staining was also used. After
edaravone (10-6-10-3 M) or saline were administered into
separate series of 6-OHDA-treated DA neurons, cells were
fixed at 18 hours as described in the previous section.
TUNEL staining was performed according to the manufac-
turer's instruction.
In order to detect the early production of superoxide ani-
ons after 6-OHDA addition, hydroethidine (HEt), selec-
tively oxidized to ehidium by superoxide anions, was
used. HEt (1 mg/ml in PBS) was administered to 6-
OHDA-treated DA neuronal cell culture at 0, 10, 20 or 30
minutes after edaravone- or saline- administration. After
5-minute incubation with HEt, the cells were washed 3
times in PBS, fixed with PFA, washed with PBS containing
DAPI and finally embedded with cover glass. The cells
were observed using a fluorescent microscope at an excita-
tion of 355 nm and an emission of 450 nm for HEt and
stained cells were counted as described above [17].
In vivo model of Parkinson's disease
Subjects
We used adult female Sprague-Dawley rats (Charles River,
Japan) weighing 250–300 g at the beginning of the exper-
iment, according to approved guidelines of the institu-
tional animal care and use committee of Okayama
University. They were housed two per cage in a tempera-
ture and humidity controlled room, maintained on a 12-
hour light/dark cycle, and they had free access to food and
water.
Surgical procedures
Seventy eight rats were deeply anesthetized with sodium
pentobarbital (30 mg/kg, i.p.) and placed in a stereotaxic
instrument (Narishige, Japan). After pre-treatment of
desipramine (25 mg/kg, i,p., Sigma), 20 μg of 6-OHDA (4
μl of 5 μg/μl dissolved in saline containing 0.2 mg/ml
ascorbic acid; Sigma) was injected into the right striatum
with a 28-gauge Hamilton syringe into the following coor-
dinates: 1.0 mm anterior to the bregma, 3.0 mm lateral to
the sagittal suture, and 5.0 mm ventral to the surface of
the brain with tooth-bar set at 0 mm [18]. The injection
rate was 1 μl/minute, and the syringe was left in place for
an additional 5 minutes before being retracted slowly (1
mm/minute). At 30 minutes or 24 hours after 6-OHDA
lesion, 30, 100, or 250 mg/kg of edaravone or saline (2
Neuroprotective effects of edaravone on 6-OHDA-treated DA neurons in vitro Figure 1
Neuroprotective effects of edaravone on 6-OHDA-treated DA neurons in vitro. Left column: TH staining of DA 
neurons (a: non-6-OHDA-treated DA neurons) demonstrates that the number of surviving 6-OHDA-treated DA neurons sig-
nificantly increased by the treatment with 10-4 and 10-3 M edaravone (e and f), compared to that with 10-6 and 10-5 M (c and d) 
edaravone as well as control without edaravone-administration (b). Scale bar: 30 μm. Right column: The graph demonstrates 
the number of surviving DA neurons by edaravone-administration. Data are shown as mean percentages of the cell number 
relative to the number of DA neurons without 6-OHDA-treatment +S.E. *p < 0.01 vs. 6-OHDA-treated DA neurons without 
edaravone-administration and those with low dose edaravone (10-6 and 10-5 M) by ANOVA.
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ml) were intravenously administered slowly from the
right femoral vein.
Behavioral testing
All rats were tested with amphetamine (2.5 mg/kg, Dain-
ippon-Seiyaku, Japan) at 1 and 2 weeks after 6-OHDA
lesion, and rotational behaviors were assessed for 60 min-
utes with a video camera. Full 360 degrees turns in the
direction ipsilateral to the lesion were counted.
Fixation and Sectioning
At 2 weeks after 6-OHDA lesion, rats were deeply anesthe-
tized with sodium pentobarbital (100 mg/kg), perfused
from the ascending aorta with 200 ml of cold PBS, fol-
lowed by 100 ml of 4% PFA in PBS. Brains were removed
and post-fixed in the same fixative for 2 days followed by
30% sucrose in phosphate buffer (PB) until to be sunk
completely. Six series of coronal sections were cut at a
thickness of 40 μm with a freezing microtome and stored
at -20 degrees C.
Immunohistochemistry
Free floating sections for TH immunohistochemistry were
blocked by 0.3% hydroxygen peroxide in methanol for 3
minutes with subsequent incubation in 1.5% normal goat
serum (Vector). Sections were then incubated overnight at
4 degrees C with rabbit anti-TH (1: 1,000; Chemicon)
antibody with 10% normal goat serum. After several
rinses in PBS, sections were incubated for 30 minutes in
biotinylated donkey anti-rabbit IgG (1: 1,000, Jackson)
then for 30 minutes in avidin-biotin-peroxidase complex
(1: 200, Vector). Subsequently the sections were treated
with 3, 4-diaminobenzidine (DAB, Sigma) and hydroxy-
gen peroxide, mounted on albumin-coated slides and
embedded with cover glass.
TUNEL and HEt staining were also performed to investi-
gate the involvement of anti-apoptotic effects and radical
scavenging activity of edaravone using 14 rats receiving
saline or 250 mg/kg of edaravone-administration at 30
minutes after 6-OHDA lesioning and sacrificed at 5 days
after 6-OHDA lesioning. Furthermore, in order to reveal
the effects of edaravone on the inflammation induced by
6-OHDA-administration, immunofluorescent Iba-1 stain-
ing was also performed. Rabbit anti-Iba-1 antibody (1:
100, Wako Pure Chemical Industries, Osaka, Japan) was
used as the primary antibody and Alexa Fluor 594 (Molec-
ular Probes) as the secondary antibody.
Morphological analysis
The density of TH-positive fibers and Iba-1-positive
microglia in the striatum of rats receiving edaravone- or
saline-infusion was determined and analyzed as described
previously with a computerized analysis system (Olym-
pus Sp-1000, Japan) [16,19] using 3 serial coronal section
at the bregma level. Two areas adjacent to the needle tract
of lesioned side and symmetrical contralateral side were
analyzed, respectively. For counting the number of TH-
positive neurons, every fifth 40 μm-thick coronal tissue
section through the substantia nigra pars compacta (SNc)
was explored using 3 coronal sections respectively at -4.8
and -5.3 mm to the bregma. The number of TH-positive
cell bodies in the SNc was counted and used for the statis-
tical analyses.
Statistical Analysis
The data obtained were evaluated statistically using anal-
ysis of variance (ANOVA) and subsequent post hoc
Scheffe's F-test or Mann-Whitney's U test. Statistical signif-
icance was preset at p < 0.05.
Results
Edaravone promotes the survival of DA neurons in vitro
We began our investigations into the neuroprotective
capacity of edaravone on 6-OHDA-treated DA neurons in
vitro. Exposure of 40 μM 6-OHDA resulted in a significant
loss of TH-positive neurons to 30.2 ± 2.5% relative to the
Reduced TUNEL-positive apoptotic 6-OHDA-treated DA  neurons with edaravone-administration in vitro Figure 2
Reduced TUNEL-positive apoptotic 6-OHDA-
treated DA neurons with edaravone-administration 
in vitro. Upper column: TUNEL-positive 6-OHDA-treated 
DA neurons with 10-3 M edaravone (b) significantly 
decreased, compared to those without edaravone-adminis-
tration (a). Scale bar: 60 μm. Lower column: The graph dem-
onstrates that TUNEL-positive 6-OHDA-treated DA 
neurons decreased by 10-4 and 10-3 M edaravone-administra-
tion. Data are shown as mean percentages of the cell number 
relative to the 6-OHDA-treated DA neurons without edar-
avone-administration +S.E. *p < 0.01 vs. 6-OHDA-treated 
DA neurons without edaravone-administration and those 
with low dose edaravone (10-6 and 10-5 M) by ANOVA. **p < 
0.01 vs. 6-OHDA-treated DA neurons without edaravone-
administration.
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unexposed control (Fig. 1). Edaravone-administration
(10-4 and 10-3 M) significantly reduced the loss of DA neu-
rons induced by 6-OHDA (81.1 ± 3.5 and 73.6 ± 2.4%),
compared to the 6-OHDA-treated DA neurons with 0, 10-
6 and 10-5 M edaravone, although 10-6 and 10-5 M edar-
avone did not exert significant reduction of the cell loss
(35.4 ± 1.9 and 35.8 ± 1.7%, One way ANOVA, F5, 102 =
125, p < 0.0001, Fig. 1).
In order to determine that edaravone suppressed cell
death through apoptosis, DA neurons were exposed to 40
μM 6-OHDA and then added 10-6, 10-5, 10-4 or 10-3 M
edaravone with subsequent counting the number of swell-
ing apoptotic cells exhibiting agglutinated and frag-
mented TUNEL-positive nuclei. Edaravone treatment (10-
3 M) significantly reduced the number of TUNEL-positive
apoptotic cells to 60.9 ± 1.7 and 82.1 ± 0.8% relative to
that of 6-OHDA-treated DA neurons without edaravone
treatment, although 10-6 and 10-5 M did not suppress
apoptosis (96.2 ± 0.7 and 97.3 ± 0.8%). 10-4 M edaravone
significantly suppressed apoptosis of DA neurons, com-
pared to 6-OHDA-treated DA neurons without edaravone
treatment (One way ANOVA, F4, 45 = 48, p < 0.0001, Fig.
2).
In order to demonstrate the production of superoxide ani-
ons, HEt staining was performed. Edaravone treatment
(10-3 M) significantly reduced the number of HEt-positive
cells (21.5 ± 0.9, 29 ± 1.1, 31 ± 2.0, and 34 ± 1.7 cells/
10,000 μm2 at 0, 10, 20, and 30 minutes after edaravone
administration), compared to the untreated 6-OHDA-
exposed cells (24.3 ± 1.7, 35.7 ± 1.7, 45.7 ± 3.3, and 62.5
± 0.9 cells/10,000 μm2 at 0, 10, 20, and 30 minutes,
Repeated Measures of ANOVA, F3, 18 = 21, p < 0.0001 and
posthoc t-tests of p's < 0.01 for 10, 20, and 30 minutes
after edaravone-administration, Fig. 3)
Behavioral analyses in vivo
Next, we proceeded to the in vivo study using PD model of
rats. There were no significant changes in the spontaneous
behavior of rats receiving edaravone-administration at 30
minutes after 6-OHDA lesion (30 mg/kg: determined by
the dose for ischemic stroke) or saline (data not shown).
As shown in Fig. 4, in PD model of rats receiving intrave-
nous saline-infusion, the number of amphetamine-
induced rotations increased over time at 1 and 2 weeks
(9.8 ± 1.1 and 11.1 ± 0.6 turns/hour). However, rats
receiving 250 mg/kg of edaravone-administration at 30
minutes after 6-OHDA lesion showed a significant reduc-
tion of the rotational number (3.8 ± 0.9 and 2.3 ± 0.7
turns/hour at 1 and 2 weeks), although 30 and 100 mg/kg
of edaravone did not exert significant effects (30 mg/kg:
9.9 ± 1.8 and 10.4 ± 1.9 turns/hour, 100 mg/kg: 6.5 ± 1.5
and 7.0 ± 1.4 turns/hour at 1 and 2 weeks, Repeated Meas-
Reduced number of HEt-positive cells by edaravone-treatment in vitros Figure 3
Reduced number of HEt-positive cells by edaravone-treatment in vitro. Left column: Edaravone treatment (10-3 M) 
significantly reduced the number of HEt-positive cells at 10, 20, 30 minutes after edaravone-administration, compared to the 
untreated 6-OHDA-exposed cells. (untreated 6-OHDA-treated DA neurons at 0 and 30 minutes (a and b); 6-OHDA-treated 
DA neurons with 10-3 M edaravone at 0 and 30 minutes (c and d). Scale bar: 30 μm. Right column: The graph demonstrates 
that HEt-positive cells significantly decreased by edaravone-administration. Data are shown as the mean cell number ± S.E. 
Dotted line: HEt-positive cells without edaravone, Full line: HEt-positive cells with 10-3 M edaravone. *p < 0.05 vs. 6-OHDA-
treated DA neurons without edaravone-administration by ANOVA.
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ures of ANOVA, F3, 24 = 8.8, p < 0.0001 and posthoc t-tests
of p's < 0.01 for both time periods, Fig. 4).
After confirmation of neuroprotective effects of intrave-
nous administration of edaravone (250 mg/kg) at 30 min-
utes after 6-OHDA lesion on 6-OHDA-treated rats
behaviorally, edaravone-administration at 24 hours were
explored. Edaravone-administration (250 and 100 mg/
kg) at 24 hours after 6-OHDA lesion significantly sup-
pressed the rotational behavior (250 mg/kg: 5.5 ± 0.4 and
4.3 ± 0.6 turns/hour, 100 mg/kg: 6.0 ± 1.9 and 6.3 ± 2.4
turns/hour at 1 and 2 weeks), compared to rats receiving
saline (10.2 ± 0.8 and 12.2 ± 0.4 turns/hour at 1 and 2
weeks, Repeated Measures of ANOVA, F3, 22 = 9.0, p =
0.0005 and posthoc t-tests of p's < 0.01 for both time peri-
ods, Fig. 4). Edaravone-administration (250 mg/kg) at 30
minutes significantly ameliorated rotational behavior,
compared to that at 24 hours after 6-OHDA lesion
(Repeated Measures of ANOVA, F1, 12 = 4.5, p = 0.04 and
posthoc t-tests of p's = 0.04 for both time periods). Thus,
edaravone significantly ameliorated the rotational behav-
ior when it was administered earlier and in higher concen-
tration.
TH immunohistochemistry in the striatum and the SNc
At 2 weeks after edaravone-()administration, TH staining
was performed to evaluate the preserved DA fibers in the
striatum and DA neurons in the SNc (Fig. 5). The density
of TH-positive fibers in the 6-OHDA-lesioned striatum
was compared with the contralateral side using a modi-
fied method of computerized image analysis system [19].
The preservation of TH-positive fibers in the striatum of
rats receiving edaravone was significantly greater (30 min-
utes: 23.3 ± 1.5, 41 ± 1.2 and 65.2 ± 1.6%; 24 hours: 20.2
± 0.9, 38.2 ± 1.7 and 51.4 ± 1.1% relative to the intact side
at the dose of 30, 100 and 250 mg/kg, respectively) than
those receiving the saline (30 minutes: 12.1 ± 0.5, 24
hours: 8.9 ± 0.3%, Repeated Measures of ANOVA, F3, 16 =
425, p < 0.0001 and posthoc t-tests of p's < 0.01 for all
groups, Fig. 6).
The number of TH-positive neurons in the ipsilateral SNc
of rats was analyzed as percentages relative to the number
Edaravone ameliorated the amphetamine-induced rotational behavior of PD model of rats Figure 4
Edaravone ameliorated the amphetamine-induced rotational behavior of PD model of rats. Left graph: Rats 
receiving 250 mg/kg of edaravone infusion at 30 minutes after 6-OHDA lesion showed a significant reduction of the rotational 
number, although 30 and 100 mg/kg of edaravone did not exert significant effects. Data are shown as the mean rotational 
number per minute ± S.E. *p < 0.05 vs. rats receiving 30 mg/kg of edaravone and those without edaravone-administration. 
Right column: Edaravone administration (250 and 100 mg/kg) at 24 hours after 6-OHDA lesion significantly suppressed the 
rotational behavior, compared to rats receiving saline. Data are shown as the mean rotational number per minute ± S.E. *p < 
0.05 vs. rats receiving 30 mg/kg of edaravone and those without edaravone-administration.
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of counted DA neurons in the intact side. The preservation
of TH-positive neurons in the SNc of rats receiving edar-
avone (100 and 250 mg/kg) was significantly greater (30
minutes: 18.5 ± 1.4, 33.5 ± 1.4 and 53.9 ± 1.4%; 24 hours:
16.4 ± 0.9, 31.8 ± 1.0 and 48.3 ± 2.3% relative to the intact
side at the dose of 30, 100 and 250 mg/kg, respectively)
than those receiving the saline (30 minutes: 12.8 ± 1.6, 24
hours: 15 ± 0.8%, Repeated Measures of ANOVA, F3, 16 =
324, p < 0.0001 and posthoc t-tests of p's < 0.01, Fig. 6).
DA fibers in the striatum of rats receiving edaravone at 30
minutes after 6-OHDA lesion was significantly preserved,
compared to those with edaravone-administration at 24
hours (p's < 0.001), although DA neurons in the SNc of
both time periods were not significantly different (p's =
0.11).
TUNEL and HEt staining for anti-apoptotic and anti-
oxidative effects
The percentages of TUNEL positive cells in the SNc of rats
receiving 250 mg/kg of edaravone at 30 minutes after 6-
OHDA lesion significantly decreased (9.6 ± 1.0%), com-
pared to those of rats without edaravone treatment (26.7
± 5.7%, Repeated Measures of ANOVA, F1, 12 = 3.4, p =
0.034 and posthoc t-tests of p's < 0.05, Fig. 7). The per-
centages of TH and HEt double positive cells per TH pos-
itive cells of rats receiving 250 mg/kg of edaravone at 30
minutes after 6-OHDA lesion significantly decreased
(12.9 ± 1.5%), compared to those of rats without edar-
avone treatment (37.7 ± 3.4%, Repeated Measures of
ANOVA, F1, 12 = 32, p < 0.001 and posthoc t-tests of p's <
0.05, Fig. 7).
Iba-1 immunohistochemistry for the affected 
inflammation
Iba-1 staining was performed to evaluate anti-inflamma-
tory effects of edaravone through the microglia. Edar-
avone administration (250 mg/kg) at 30 minutes after 6-
OHDA lesion significantly suppressed the number of Iba-
1-positive cells (178 ± 4.2 cells/10,000 μm2; non-edar-
avone-administered group: 252 ± 14 cells/10,000 μm2),
thus indicating that edaravone suppressed inflammation
induced by 6-OHDA with the decrease of activated micro-
glia (p < 0.05, Mann-Whitney's U test, Fig. 8).
Discussion
In this study, neuroprotective effects of edaravone on 6-
OHDA-treated murine ventral mesencephalic DA neurons
were clarified in vitro. Anti-apoptotic effects through scav-
enging radicals might play an important role in the under-
lying mechanisms of neuroprotective effects of edaravone.
In parallel, neuroprotective effects of edaravone on 6-
OHDA-lesioned PD model of rats were demonstrated
behaviorally and immunohistochemically. Edaravone
might exert the neuroprotective effects on DA neurons.
TUNEL, HEt and Iba-1 staining suggested the involvement
of anti-apoptotic, anti-oxidative and anti-inflammatory
effects of edaravone.
Anti-apoptotic effects of edaravone
Neuroprotective effects of edaravone might be mediated
by anti-apoptotic effects. Against ischemic reperfusion,
edaravone prevents cell death and the release of cyto-
chrome c with subsequent pathological apoptosis
Preserved TH-positive fibers in the striatum and neurons in the SNc of rats receiving edaravone-administration Figure 5
Preserved TH-positive fibers in the striatum and neurons in the SNc of rats receiving edaravone-administra-
tion. Photomicrographs demonstrate that 100 and 250 mg/kg of edaravone preserved TH immunoreactivity in the striatum 
and SNc (edaravone-administration at 30 minutes after 6-OHDA lesion, 30 mg/kg: c and i, 100 mg/kg: d and J, 250 mg/kg: e and 
k, edaravone administration at 24 hours after 6-OHDA lesion, 250 mg/kg: f and l), compared to the untreated 6-OHDA-
lesioned rats (b and h). TH staining of the intact side of the striatum and SNc: a and h, TH staining of the striatum: a-f, and the 
SNc: g-l. Scale bar: 120 μm in a-f, 480 μm in g-l.
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through Bcl-2 upregulation by inhibiting the opening of
the mitochondrial permeability transposition pore
[20,21]. In parallel, edaravone might reduce Fas-associ-
ated death domain protein and subsequently suppress
apoptotic cell death in cerebral infarct [22]. Furthermore,
edaravone might alleviate dysfunction of endoplasmic
reticulum with subsequent cell death in cerebral ischemia
[23]. Edaravone also reduces nitric oxide-induced apopto-
sis by inhibiting activation of MAP kinase in astroctes
[24]. Related to 6-OHDA-toxicity, apoptosis is induced by
down-regulation of Bcl-2 with activation of caspases in
thymocytes [25], which might be suppressed by edar-
avone. Activated microglia damages surrounding cells by
the paracrine of various cytokines. Using co-culture of
neuronal cells and microglia, neuronal cell death by the
peroxynitrite donor, SIN-1 (N-morpholinosydnonimine)
is significantly suppressed by 10-4 M edaravone [15]. In
our study, the number of TUNEL-positive apoptotic cells
and HEt-positive cells decreased using both in vitro and in
vivo model of PD. The number of activated microglia of
rats receiving 250 mg/kg of edaravone decreased, suggest-
ing that the reduced cytotoxic cytokines might suppress
apoptosis synergistically. The underlying mechanisms of
the neuroprotection of edaravone might be involved in
the hypothesis above described.
Characteristics of our study
Recently, the similar study was reported using 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice
[26]. MPTP activated microglial activation both in the
striatum and SNc with the increase of 3-nitrotyrosine, a
biomarker of peroxynitrite production, in the SNc, but
not in the striatum. Intraperitoneal 3 mg/kg of edaravone
significantly ameliorate the behavioral scores, however
the neuroprotective effects might be limited in the SNc.
Using the animal model of cerebral infarct and head
trauma, Dohi and colleagues also demonstrated the neu-
roprotective effects of low dose of edaravone [13]. In our
study, the neuroprotective effects of edaravone (100 and
250 mg/kg) was demonstrated both in the striatum and
Edaravone-administration exerted neuroprotective effects in a dose-responsive manner immunohistochemically in vivo Figure 6
Edaravone-administration exerted neuroprotective effects in a dose-responsive manner immunohistochemi-
cally in vivo. Left graph: TH staining of the striatum demonstrates neuroprotective effects of edaravone on 6-OHDA-lesioned 
striatal DA fibers in a dose-responsive manner. Data are shown as the percentages of TH-positive fibers relative to the intact 
side ± S.E. *p < 0.05 vs. rats in all other groups, **p < 0.05 vs. rats receiving 30 mg/kg of edaravone and those without edar-
avone-administration, ***p < 0.05 vs. rats without edaravone-administration, ****p < 0.05 (rats receiving edaravone at 30 min-
utes after 6-OHDA lesion (30 min group) vs. rats with edaravone at 24 hours (24 h group)). Right graph: TH staining of the 
SNc demonstrates neuroprotective effects of edaravone on 6-OHDA-lesioned striatal DA fibers in a dose-responsive manner. 
Data are shown as the percentages of TH-positive neurons relative to the intact side ± S.E. *p < 0.05 vs. rats in all other 
groups, **p < 0.05 vs. rats receiving 30 mg/kg of edaravone and those without edaravone-administration.
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SNc, although 30 mg/kg did not exert any neuroprotective
effects, except for the histological amelioration in the
striatum. Additionally, the behavioral amelioration by
100 mg/kg of edaravone-administered at 30 minutes and
24 hours after 6-OHDA lesioning did not show time-
dependency. Furthermore, the lower dosage of edaravone
(3 and 10 mg/kg) exerted no neuroprotective effects in
our pilot study (data not shown). These discrepancies of
the results might be due to the alteration of edaravone-
activity and affinity over time after lesioning, the charac-
teristics of the behavioral test, or the differences of the
toxin (MPTP vs. 6-OHDA), of the administration route
(i.p. vs. i.v.), of the animal species (mice vs. rat), and of
the detailed regimen. For the safe clinical application,
some amelioration of the drug, including the enhanced
action for neurons specifically, because edaravone-admin-
istration even at clinical dosage might result in severe side
effects [27].
Until now several studies demonstrated neuroprotective
effects of pre-treatment of edaravone against metamphet-
amine-toxicity on striatal dopaminergic degeneration [28]
and post-ischemic dopaminergic dysfunctions [29]. One
of the remarkable characteristics of our study also lie in
the time-dependent effects of edaravone, that is, the ear-
lier (at 30 minutes after 6-OHDA lesion) administration
might exert significantly stronger neuroprotective effects
than the later one (at 24 hours), mimicking the clinical
settings, although the later administration still displayed
the behavioral and histological amelioration. In the
future, the effects of repeated administration of edaravone
on PD model should be clarified.
Therapy for PD in the future including edaravone-
administration
The established therapy for PD is medication using L-
DOPA (dihydroxyphenylalanine), DA agonist and vari-
ous drugs of different mechanisms, surgeries including
electrical stimulation and ablation [30]. Fetal cell trans-
plantation and GDNF infusion [31] are also hopeful,
although the recent double-blinded randomized control-
led trials questioned us the efficacy of these therapy
[32,33]. In the nearest preceding years, neural transplan-
tation might be a hopeful therapeutic option for PD [34]
with recent development in the stem cell biology [35-40].
When edaravone is used for PD patients, several advan-
tages might be recognized in combination with other
therapeutic options. As edaravone extends the therapeutic
time window for ischemic patients in combination with
tissue plasminogen activator [41], edaravone might amel-
iorate the survival of transplanted cells [42] as well as
scavenge free radicals in PD. Edaravone might also sup-
press inflammatory reaction induced by surgical proce-
dures including electrical stimulation and cell
transplantation.
Conclusion
Neuroprotective effects of edaravone on 6-OHDA-treated
DA neurons were clarified in vitro. Anti-apoptotic effects
and radical scavenging activity might be involved in the
underlying mechanisms of neuroprotective effects of edar-
avone. Neuroprotective effects of edaravone were then
demonstrated using animal model of PD. Edaravone
might be a hopeful therapeutic option for PD, although
several critical issues remain to be solved, including high
therapeutic dosage of edaravone for the safe clinical appli-
cation in the future.
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